Recombinant human granulocyte colony stimulating factors: therapeutic application in the prevention of chemotherapy-induced neutropenia.
Gabrilove
J L
JL
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York.
Jakubowski
A
A
Scher
H
H
Sternberg
C
C
Wong
G
G
Grous
J
J
Yagoda
A
A
Fain
K
K
Moore
M A
MA
Clarkson
B
B
D000380:Agranulocytosis / Q000517:prevention & control*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003115:Colony-Stimulating Factors / Q000627:therapeutic use* / Q000633:toxicity; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D016179:Granulocyte Colony-Stimulating Factor; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000209:etiology / Q000517:prevention & control*; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use* / Q000633:toxicity; D014747:Vinblastine / Q000008:administration & dosage
D003115:Colony-Stimulating Factors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate